A 6.5-month-old boy with the rare inherited urea cycle disorder ornithine transcarbamylase (OTC) deficiency has responded positively in a targeted in vivo gene editing trial, in which a correct copy ...
The Recombinant DNA Advisory Committee (RAC), the National Institutes of Health office responsible for public oversight of gene therapy, met on 8–10 December to examine the clinical trial in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback